文献速递免疫规划卫生政策与健康促进

接受免疫抑制靶向治疗者的疫苗可预防疾病免疫

Immunisation against vaccine-preventable diseases in individuals receiving immunosuppressive targeted therapies.
PubMed 文献 · Vaccine · 2026-03-03

本综述总结接受生物制剂和小分子靶向治疗患者的感染风险、疫苗效力和安全性证据。不同靶向治疗的感染风险和疫苗反应差异很大,淋巴细胞清除性治疗可致疫苗反应不足,同时使用免疫抑制剂与严重感染风险升高相关。现有证据多来自非随机试验和观察性研究,需在免疫受损人群中开展前瞻性试验。

要点

  • 靶向治疗的感染风险和疫苗反应因药物而异,淋巴细胞清除性药物风险最高。
  • 疫苗免疫原性数据主要集中在新冠、流感和肺炎球菌疫苗。
  • 减毒活疫苗安全性仍是靶向治疗患者的重要顾虑,但严重不良事件罕见。

核心结论

  • 接受靶向治疗者的感染风险和疫苗反应因药物而异,从显著到可忽略不等。
  • 淋巴细胞清除性治疗可导致疫苗反应不足,且受基础疾病和合并免疫抑制剂影响。
  • 减毒活疫苗安全性仍是重要关注点,但严重不良事件罕见。

研究设计与样本

  • 综述总结了接受靶向治疗患者感染风险、疫苗效力和安全性的当前证据。

主要发现

  • 感染风险和疫苗反应范围从显著(如阿仑单抗、利妥昔单抗)到可忽略(如美泊利珠单抗、伊马替尼)。
  • 严重感染风险较高与同时接受免疫抑制药物相关。
  • 疫苗免疫原性数据主要限于COVID-19、流感和肺炎球菌疫苗,带状疱疹和乙型肝炎疫苗研究较少。
  • 许多靶向治疗常损害疫苗反应,但很少完全消除。
  • 淋巴细胞清除性治疗可导致疫苗反应不足,且常受基础疾病和合并免疫抑制剂影响。

临床怎么用

  • 临床医生应认识到不同靶向治疗对感染风险和疫苗反应的影响差异很大。
  • 对接受淋巴细胞清除性治疗或合并免疫抑制剂的患者,需特别关注疫苗反应可能不足。
  • 为靶向治疗患者接种减毒活疫苗时,应权衡罕见严重不良事件的风险。

局限性

  • 当前证据主要基于非随机试验和观察性研究,限制了结论的强度。
  • 未来试验需纳入免疫受损个体以准确评估疫苗免疫原性、临床效力和安全性。
  • 需要更好的预测模型或生物标志物来分层风险和预测疫苗效力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The availability and clinical use of biological and small molecule targeted therapies is rapidly expanding. The intricate nature of their mechanisms and the impact of the underlying condition make it challenging for clinicians to anticipate the infectious risks and vaccination outcomes for individuals prescribed these therapies. We aimed to summarise the current evidence focusing on the risk of infections, vaccine efficacy and vaccine safety in patients receiving targeted therapies. Our review revealed variable infection risks and vaccine responses in patients on targeted therapies, ranging from dramatic (e.g., alemtuzumab, rituximab) to negligible (e.g., mepolizumab, imatinib). Higher risks of serious infection were associated with receipt of concomitant immunosuppressive medications. Vaccine immunogenicity data were predominantly restricted to COVID-19, influenza, and pneumococcal vaccines, with fewer studies on herpes zoster and hepatitis B vaccines. Vaccine responses were often impaired by many targeted therapies, but rarely eliminated. Therapies with lymphocyte-depleting effects, however, can result in inadequate vaccine responses, and were often affected by underlying conditions and concomitant immunosuppressants. Live vaccine safety remains a prominent concern for patients prescribed targeted therapies, though serious adverse events are rare. Current evidence is largely based on non-randomised trials and observational studies, which limits the strength of conclusions that can be drawn. To address this gap and ensure accurate evaluation of vaccine immunogenicity, clinical efficacy and safety, it is essential that future trials include immunocompromised individuals. Better prediction models or biomarkers for stratifying risk and predicting vaccine efficacy are also important further steps.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Wang X, Patel C, Sharma K, et al. Immunisation against vaccine-preventable diseases in individuals receiving immunosuppressive targeted therapies. Vaccine. 2026. PMID: 41780104. doi:10.1016/j.vaccine.2026.128399

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。